INTEGRATED BIOPHARMA INC (INBP) FY2026 Annual Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2025-07-01 to 2026-06-30

Swipe to see the full flow
INTEGRATED BIOPHARMA INC cash flow reconciliation, Jul 1, 2025 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Accounts receivable → operating reconciliation: $2,096,000.00Amortization of right-of-use assets → operating reconciliation: $1,095,000.00Accounts payable → operating reconciliation: $925,000.00Depreciation and amortization → operating reconciliation: $293,000.00Deferred income taxes, net → operating reconciliation: $258,000.00Inventories → operating reconciliation: $220,000.00Compensation expense on employee stock options → operating reconciliation: $192,000.00Accrued expenses and other current liabilities → operating reconciliation: $91,000.00Impairment charge on equipment → operating reconciliation: $30,000.00Other, net → operating reconciliation: $12,000.00operating reconciliation → Net cash from operating activities: $1,241,000.00operating reconciliation → Net (loss) income: $2,842,000.00operating reconciliation → Operating lease obligations: $1,034,000.00operating reconciliation → Other assets: $89,000.00operating reconciliation → Loss on disposal of fixed assets: $6,000.00Proceeds from sale of property and equipment → investing reconciliation: $6,000.00Net cash used in investing activities → investing reconciliation: $340,000.00investing reconciliation → Purchase of property and equipment: $346,000.00Net cash used in financing activities → financing reconciliation: $45,000.00financing reconciliation → Repayments under financed lease obligations: $45,000.00Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations → Cash sources and uses: $3,615,000.00Net cash from operating activities → Cash sources and uses: $1,241,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $4,471,000.00Cash sources and uses → Net cash used in investing activities: $340,000.00Cash sources and uses → Net cash used in financing activities: $45,000.00Allowance for (charge offs of) uncollectible accounts receivable, net: $0.00Loss on disposal of fixed assets: -$6,000.00PP&E disposal gain & loss−$6.00 KDeferred income taxes, net: $258,000.00Deferred income taxes+$258.00 KCompensation expense on employee stock options: $192,000.00Stock-based compensation+$192.00 KAccounts receivable: $2,096,000.00Accounts receivable+$2.10 MInventories: $220,000.00Inventories+$220.00 KImpairment charge on equipment: $30,000.00Asset impairments+$30.00 KOther, net: $12,000.00Other operating, net+$12.00 KAccounts payable: $925,000.00Accounts payable+$925.00 KAccrued expenses and other current liabilities: $91,000.00Other accrued liabilities+$91.00 KOther assets: -$89,000.00Other current assets−$89.00 KOperating lease obligations: -$1,034,000.00Operating lease liabilities−$1.03 MAmortization of right-of-use assets: $1,095,000.00Operating lease amortization+$1.10 MDepreciation and amortization: $293,000.00Depreciation & amortization+$293.00 KNet (loss) income: -$2,842,000.00Net (loss) income−$2.84 MNet cash from operating activities: $1,241,000.00Operating cash+$1.24 Moperating reconciliation: $5,212,000.00Repayments under financed lease obligations: -$45,000.00Finance lease payments−$45.00 KProceeds from exercises of stock options: $0.00Net cash used in financing activities: -$45,000.00. Cash required to fund net payments.Financing cash−$45.00 Kfinancing reconciliation: $45,000.00Purchase portion of right of use asset - financed: $0.00Proceeds from sale of property and equipment: $6,000.00PP&E sales+$6.00 KPurchase of property and equipment: -$346,000.00PP&E purchases−$346.00 KNet cash used in investing activities: -$340,000.00. Cash required to fund net payments.Investing cash−$340.00 Kinvesting reconciliation: $346,000.00Cash sources and uses: $4,856,000.00Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $3,615,000.00Beginning cash$3.62 MEnding cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $4,471,000.00Ending cash$4.47 MCASH RECONCILIATIONOperatingflowsInvestingflowsFinancingflowsNet loss −$2.84M + net operating adjustments $4.08M = operating cash +$1.24MFree cash flow$895.00 KOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change+$856.00 KEnding cash − beginning cash
Chart details

INTEGRATED BIOPHARMA INC cash flow reconciliation, Jul 1, 2025 through Jun 30, 2026

Cash flows for Jul 1, 2025 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations. Beginning cash: Jun 30, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Jun 30, 2025
3,615,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations
Operating activities
1,241,000 US dollars. Net cash provided.
Net (loss) income
negative 2,842,000 US dollars
Allowance for (charge offs of) uncollectible accounts receivable, net
0 US dollars
Loss on disposal of fixed assets
negative 6,000 US dollars
Deferred income taxes, net
258,000 US dollars
Compensation expense on employee stock options
192,000 US dollars
Accounts receivable
2,096,000 US dollars
Inventories
220,000 US dollars
Impairment charge on equipment
30,000 US dollars
Other, net
12,000 US dollars
Accounts payable
925,000 US dollars
Accrued expenses and other current liabilities
91,000 US dollars
Other assets
negative 89,000 US dollars
Operating lease obligations
negative 1,034,000 US dollars
Amortization of right-of-use assets
1,095,000 US dollars
Depreciation and amortization
293,000 US dollars
Investing activities
negative 340,000 US dollars. Net cash used.
Purchase portion of right of use asset - financed
0 US dollars
Proceeds from sale of property and equipment
6,000 US dollars
Purchase of property and equipment
negative 346,000 US dollars
Financing activities
negative 45,000 US dollars. Net cash used.
Repayments under financed lease obligations
negative 45,000 US dollars
Proceeds from exercises of stock options
0 US dollars
Operating adjustment reconciliation
5,212,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
45,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
346,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
0 US dollars
Ending cash on Jun 30, 2026
4,471,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations
Cash sources and uses
4,856,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
856,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
1,241,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
346,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
895,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$2.84M + net operating adjustments $4.08M = operating cash +$1.24M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 1,241,000 US dollars minus 346,000 US dollars equals 895,000 US dollars.
INTEGRATED BIOPHARMA INC (INBP) FY2026 Annual Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!